An investigational therapy significantly shrank lung cancer tumors that are notoriously resistant to treatment by encouraging ...

New antibody AHA-1031 shows potential in treating non small cell lung cancer resistant to immunotherapy, offering new hope.

Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT), a developer of innovative precision diagnostics and laboratory services, announced today that it has received a Notice of Allowance ...

Avalon GloboCare Corp. ("Avalon" or the "Company") (NASDAQ: ALBT), a developer of innovative precision diagnostics and laboratory services, announced ...

United States Department of Pathology and Immunology, Washington University School of Medicine, St Louis, United States Bursky Center for Human Immunology and Immunotherapy Programs, Washington ...

“We’re excited about the potential of this new strategy,” said Dr. Xiaowei “George” Xu, a Penn Pathology and Laboratory ... from natural killer (NK) cells, a type of immune cell ...

1Masonic Cancer Center, Minneapolis, Minnesota. 6Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, Minnesota. 7Department of ...

Biomissile Pharmaceuticals Co. Ltd. is developing multispecific antibodies that overcome resistance associated with antibody-drug conjugates via its next-generation natural killer (NK) cell engagers.

Researchers at The Wistar Institute's HIV Cure and Viral Diseases Center have successfully identified a new approach using ...

Within the immune system, interleukin-15 (IL-15) plays a relevant role by boosting the number of cytotoxic T cells and NK cells, the major drivers of anticancer immune response. Researchers from Sotio ...

Gilead Sciences' cell therapy Kite Pharma has bulked up its position in natural killer (NK) cell therapies, pledging up to $2.3 billion for a partnership with Shoreline Bioscience focusing on off ...